Related Experiment Video

Updated: Aug 22, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

SRCircumventing imatinib resistance

Michael W N Deininger1, Brian J Druker

  • 1Oregon Health & Science University Cancer Institute, Center for Hematologic Malignancies, L592, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.

Cancer Cell
|August 25, 2004
PubMed

Insights

Imatinib resistance in chronic myeloid leukemia is often caused by BCR-ABL mutations. New ABL inhibitors show promise in overcoming these mutations, offering hope for patients with relapsed disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Imatinib is a key therapy for chronic myeloid leukemia (CML).
  • Relapse in CML patients treated with imatinib is frequently linked to BCR-ABL gene mutations.
  • These mutations confer resistance to imatinib therapy.

Purpose of the Study:

  • To investigate alternative ABL inhibitors targeting BCR-ABL mutations.
  • To understand the structural mechanisms of action and resistance related to these inhibitors.
  • To evaluate the efficacy of novel inhibitors against common BCR-ABL mutations.

Main Methods:

  • Identification and characterization of alternative ABL inhibitors.
  • Structural analysis to elucidate drug-target interactions.
  • Preclinical studies assessing inhibition of BCR-ABL mutants.

Main Results:

  • Several alternative ABL inhibitors effectively target common BCR-ABL mutations.
  • Structural studies provide insights into inhibitor mechanisms and resistance pathways.
  • One novel inhibitor has advanced to clinical trials.

Conclusions:

  • Alternative ABL inhibitors represent a promising strategy for managing imatinib-resistant CML.
  • Understanding resistance mechanisms is crucial for developing effective targeted therapies.
  • Integrated scientific and clinical studies are vital for therapeutic advancement.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...